Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Published Date: 13 Sep 2024

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of cancer is decreased by following international health recommendations.

2.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

3.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

4.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

5.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot